Success Metrics

Completion Rate
0%(0/3)
Active Trials
2(40%)
Terminated
3(60%)

Phase Distribution

Ph not_applicable
2
40%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution2 total trials
N/ANon-phased studies
2(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

0.0%

0 of 3 finished

Non-Completion Rate

100.0%

3 ended early

Currently Active

2

trials recruiting

Total Trials

5

all time

Status Distribution
Active(2)
Terminated(3)

Detailed Status

Terminated3
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
2
Success Rate
0.0%
Most Advanced
N/A

Trials by Phase

N/A2 (100.0%)

Trials by Status

terminated360%
recruiting240%

Recent Activity

2 active trials
Showing 5 of 5
recruitingnot_applicable

Positioning of Molecular Markers in Clinical Routine for the Management of Patients With Adrenal Cancers/Tumors (COMETE-CARE)

NCT05754892
recruitingnot_applicable

Prospective Cohort of Patients With Newly Diagnosed Glioblastoma: Analysis of MMP2 and MMP9 Expression and Correlation to Neuro-imaging Features.

NCT03526822
terminated

Sample Collection From Melanoma Patients

NCT00507325
terminated

The Effect of Radiotherapy and Temozolomide on the Tumor Vasculature and Stem Cells in Human High-grade Astrocytomas

NCT00473408
terminated

Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer

NCT01232881

Clinical Trials (5)

Showing 5 of 5 trials
NCT05754892Not Applicable

Positioning of Molecular Markers in Clinical Routine for the Management of Patients With Adrenal Cancers/Tumors (COMETE-CARE)

Recruiting
NCT03526822Not Applicable

Prospective Cohort of Patients With Newly Diagnosed Glioblastoma: Analysis of MMP2 and MMP9 Expression and Correlation to Neuro-imaging Features.

Recruiting
NCT00507325

Sample Collection From Melanoma Patients

Terminated
NCT00473408

The Effect of Radiotherapy and Temozolomide on the Tumor Vasculature and Stem Cells in Human High-grade Astrocytomas

Terminated
NCT01232881

Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer

Terminated

All 5 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
5